GE Healthcare, Oxford to Study Feasibility Of Pairing In Vivo and In Vitro Technologies | GenomeWeb

GE Healthcare said last week it will embark on a broad collaboration with researchers at the University of Oxford to study the use of medical imaging and genomic profiling to improve the treatment of colorectal cancer.

The partnership, to which GE will contribute $3 million, might be the first of similar collaborations that the company could forge that focus on pairing in vitro and in vivo technologies for drug and diagnostic development, which was a key reason for GE's acquisition of Amersham in 2004.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.